Criterium, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1991-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.criteriuminc.com
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
Phase 1
Completed
- Conditions
- AmyloidosisSystemic Light Chain Amyloidosis
- Interventions
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01789242
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
Phase 1
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01660750
- Locations
- 🇺🇸
Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California, United States
🇺🇸University of Massachusettes Memorial, Worcester, Massachusetts, United States
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1
Terminated
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT01464034
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸The John Theurer Cancer Center @ Hackensack UMC, Hackensack, New Jersey, United States